You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Cyproheptadine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cyproheptadine hydrochloride and what is the scope of freedom to operate?

Cyproheptadine hydrochloride is the generic ingredient in two branded drugs marketed by Actavis Mid Atlantic, Chartwell Molecular, Elysium, Halsey, Lyne, Morton Grove, Naska, Patrin, Pharm Assoc, Quagen, Tris Pharma Inc, Merck, Am Therap, Appco, Ascot, Beximco Pharms Usa, Chartwell Rx, Duramed Pharms Barr, Heritage Pharma, Kenton, Kv Pharm, Md Pharm, Mountain, Mylan, Novast Labs, Pioneer Pharms, Pliva, Rising, Strides Pharma, Superpharm, Vitarine, Watson Labs, and Zydus Pharms, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for cyproheptadine hydrochloride. Twenty-three suppliers are listed for this compound.

Summary for cyproheptadine hydrochloride
US Patents:0
Tradenames:2
Applicants:33
NDAs:41
Drug Master File Entries: 2
Finished Product Suppliers / Packagers: 23
Raw Ingredient (Bulk) Api Vendors: 92
Clinical Trials: 29
Patent Applications: 1,471
What excipients (inactive ingredients) are in cyproheptadine hydrochloride?cyproheptadine hydrochloride excipients list
DailyMed Link:cyproheptadine hydrochloride at DailyMed
Recent Clinical Trials for cyproheptadine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kinnov TherapeuticsPhase 1
National Center for Advancing Translational Sciences (NCATS)Phase 2/Phase 3
Corey HawesPhase 2/Phase 3

See all cyproheptadine hydrochloride clinical trials

Medical Subject Heading (MeSH) Categories for cyproheptadine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for cyproheptadine hydrochloride

US Patents and Regulatory Information for cyproheptadine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elysium CYPROHEPTADINE HYDROCHLORIDE cyproheptadine hydrochloride SYRUP;ORAL 209108-001 Oct 16, 2018 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Md Pharm CYPROHEPTADINE HYDROCHLORIDE cyproheptadine hydrochloride TABLET;ORAL 087566-001 Nov 10, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs CYPROHEPTADINE HYDROCHLORIDE cyproheptadine hydrochloride TABLET;ORAL 086580-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Strides Pharma CYPROHEPTADINE HYDROCHLORIDE cyproheptadine hydrochloride TABLET;ORAL 087129-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Molecular CYPROHEPTADINE HYDROCHLORIDE cyproheptadine hydrochloride SYRUP;ORAL 203191-001 Jul 13, 2017 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.